Citi analyst Yigal Nochomovitz downgraded Harpoon Therapeutics (HARP) to Neutral from Buy with a $23 price target following the proposed acquisition by Merck (MRK) for $23 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HARP:
- Harpoon Therapeutics Nears Merger Completion with Merck
- Harpoon Therapeutics Announces Reverse Stock Split Update
- Harpoon Therapeutics downgraded to Market Perform from Outperform at TD Cowen
- Biotech Alert: Searches spiking for these stocks today
- Oppenheimer raises Harpoon target, wonders if Merck deal could be starting point